Lipegfilgrastim

證據等級: L5

預測適應症: 10 個

Lipegfilgrastim: From Chemotherapy-Induced Neutropenia to Primary Release Disorder of Platelets

One-Sentence Summary

Lipegfilgrastim is a pegylated G-CSF (granulocyte colony-stimulating factor) analogue, approved for chemotherapy-induced neutropenia. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but currently no clinical trials and no publications support this direction — the prediction rests on knowledge-graph similarity alone.

Quick Overview

Item	Content
Original Indication	Chemotherapy-induced neutropenia (G-CSF receptor agonist)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.93%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for lipegfilgrastim is not available in this evidence pack (marked as a data gap). Based on known information, lipegfilgrastim is a pegylated G-CSF analogue that acts on the G-CSF receptor to stimulate proliferation and differentiation of granulocytes (neutrophils); its approved use is chemotherapy-induced neutropenia.

Primary release disorder of platelets is a platelet-function/production disorder with a distinct pathophysiology from neutrophil regulation. There is no established literature connecting G-CSF receptor signalling to platelet release mechanisms. While G-CSF-driven bone marrow stem cell mobilization could theoretically have indirect effects on megakaryocyte/platelet production, this link is speculative and not supported by any primary mechanistic data in the evidence pack.

In short, this prediction is a pure knowledge-graph embedding similarity result from TxGNN, with low mechanistic plausibility and no corroborating clinical or literature evidence at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Lipegfilgrastim currently has no marketing authorisation on record in Denmark (market status: Not marketed; 0 authorisations).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is supported only by a TxGNN model prediction score (L5 evidence) — there are no clinical trials, no published literature, and no established mechanistic link between G-CSF receptor activity and platelet release disorders. The drug is also not currently marketed in Denmark.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for lipegfilgrastim
Danish/EU Summary of Product Characteristics (SmPC) warnings, contraindications, and drug interaction data
Preclinical or mechanistic studies linking G-CSF pathway activity to platelet release disorders
Any emerging clinical trial or case-report evidence before advancing beyond model-prediction stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.